This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tabori, U. Articles by Malkin, D. Search for Related Content PubMed PubMed Citation Articles by Tabori, U. Articles by Malkin, D.

Younger Age of Cancer Initiation Is Associated with Shorter Telomere Length in Li-Fraumeni Syndrome

¹ Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, and ² Department of Medical Biophysics, University of Toronto, Toronto, Canada

Requests for reprints: David Malkin, Division of Hematology/Oncology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. Phone: 416-813-5348; Fax: 416-813-5327; E-mail: david.malkin{at}sickkids.ca.

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome frequently associated with germ line TP53 mutations. Unpredictable and disparate age of cancer onset is a major challenge in the management of LFS. Genetic modifiers, including the MDM2-SNP309 polymorphism, and genetic anticipation have been suggested as plausible explanations for young age of tumor onset, but the molecular mechanisms for these observations are unknown. We speculated that telomere attrition will increase genomic instability and cause earlier tumor onset in successive generations. We analyzed mean telomere length and MDM2-SNP309 polymorphism status in individuals from multiple LFS families and controls. A total of 45 peripheral blood lymphocyte samples were analyzed from 9 LFS families and 15 controls. High rate of MDM2-SNP309 was found in TP53 carriers (P = 0.0003). In children, telomere length was shorter in carriers affected with cancer than in nonaffected carriers and wild-type controls (P < 0.0001). The same pattern was seen in adults (P = 0.002). Within each family, telomere length was shorter in children with cancer than in their nonaffected siblings and their noncarrier parents. Telomere attrition between children and adults was faster in carriers than in controls. Our results support the role of MDM2-SNP309 as a genetic modifier in LFS. The novel finding of accelerated telomere attrition in LFS suggests that telomere length could explain earlier age of onset in successive generations of the same family with identical TP53/MDM2-SNP309 genotypes. Furthermore, telomere shortening could predict genetic anticipation observed in LFS and may serve as the first rational biological marker for clinical monitoring of these patients. [Cancer Res 2007;67(4):1415–8

This article has been cited by other articles:

				T. Else Telomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging J. Mol. Endocrinol., October 1, 2009; 43(4): 131 - 141. [Abstract] [Full Text] [PDF]

				F. Song, H. Zheng, B. Liu, S. Wei, H. Dai, L. Zhang, G. A. Calin, X. Hao, Q. Wei, W. Zhang, et al. An miR-502-Binding Site Single-Nucleotide Polymorphism in the 3'-Untranslated Region of the SET8 Gene Is Associated with Early Age of Breast Cancer Onset Clin. Cancer Res., October 1, 2009; 15(19): 6292 - 6300. [Abstract] [Full Text] [PDF]

				C. G. Parks, D. B. Miller, E. C. McCanlies, R. M. Cawthon, M. E. Andrew, L. A. DeRoo, and D. P. Sandler Telomere Length, Current Perceived Stress, and Urinary Stress Hormones in Women Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 551 - 560. [Abstract] [Full Text] [PDF]

				M. Nilbert, S. Timshel, I. Bernstein, and K. Larsen Role for Genetic Anticipation in Lynch Syndrome J. Clin. Oncol., January 20, 2009; 27(3): 360 - 364. [Abstract] [Full Text] [PDF]

				S. B. Gruber and B. Mukherjee Anticipation in Lynch Syndrome: Still Waiting for the Answer J. Clin. Oncol., January 20, 2009; 27(3): 326 - 327. [Full Text] [PDF]

				O. Landgren, L. R. Goldin, S. Y. Kristinsson, E. A. Helgadottir, J. Samuelsson, and M. Bjorkholm Response: More on disease anticipation in familial MPN Blood, September 15, 2008; 112(6): 2588 - 2589. [Full Text] [PDF]

				A. Shlien, U. Tabori, C. R. Marshall, M. Pienkowska, L. Feuk, A. Novokmet, S. Nanda, H. Druker, S. W. Scherer, and D. Malkin Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome PNAS, August 12, 2008; 105(32): 11264 - 11269. [Abstract] [Full Text] [PDF]

				U. Tabori and D. Malkin Risk Stratification in Cancer Predisposition Syndromes: Lessons Learned from Novel Molecular Developments in Li-Fraumeni Syndrome Cancer Res., April 1, 2008; 68(7): 2053 - 2057. [Abstract] [Full Text] [PDF]

				G. Aubert and P. M. Lansdorp Telomeres and Aging Physiol Rev, April 1, 2008; 88(2): 557 - 579. [Abstract] [Full Text] [PDF]

				R. A. Risques, T. L. Vaughan, X. Li, R. D. Odze, P. L. Blount, K. Ayub, J. L. Gallaher, B. J. Reid, and P. S. Rabinovitch Leukocyte Telomere Length Predicts Cancer Risk in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2649 - 2655. [Abstract] [Full Text] [PDF]

				Z. Hu, G. Jin, L. Wang, F. Chen, X. Wang, and H. Shen MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2717 - 2723. [Abstract] [Full Text] [PDF]